Chikungunya vaccine candidate: Antibody levels remained stable from month 6 to month 12
by NewsDesk Lord, save her
vaccine company, ValnevaOn Monday, it announced positive data on persistence of antibodies twelve months after vaccination with a single dose of the chikungunya vaccine, VLA1553.
Following positive immunogenicity and safety data for the Phase 3 VLA1553-301 study in March 2022, Valneva set up a custom antibody persistence trial (VLA1553-303) to monitor a subset of participants for at least five years and confirm the expected long-term robustness of the antibody response after a single vaccination.
The antibody continuity trial enrolled 363 healthy adult participants and followed them from month 6 after vaccination to month 12. 99% of participants maintained neutralizing antibody titers above the serologic response threshold of 150 12 months after single-dose vaccination. These antibody levels confirm the antibody persistence profile observed in a previous study. Antibody persistence was similar in elderly subjects ≥65 years of age, who maintained neutralizing antibody titers compared to younger adults throughout follow-up. These findings follow the completion of the pivotal study VLA1553-301, which had a serologic response rate of 96% six months after vaccination.1 It has been reported. The study will continue to monitor the persistence of antibodies on an annual basis.
No safety concerns were identified throughout the duration of the follow-up study, confirming the safety profile noted in previous studies.
“We are excited about this 12-month data which is in line with what we saw from the previous reading in the sixth month, and strengthens the prospects of inducing a prolonged antibody response with our chikungunya vaccine candidate,” said Dr. Juan Carlos Jaramillo, Valneva’s chief medical officer. “We look forward to completing the submission of rolling BLA to the FDA and possibly changing lives. If our experimental vaccine is approved, we are confident it can help address this large and growing unmet public health threat.”